AKTS

Akoustis Technologies Inc. (AKTS) | Rumor.io

Akoustis Technologies

AKTS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,585

Bullish sentiment (50-day avg)99%

Price to earnings ratio-16

Market capitalization1.1B

Earnings per share-1.32

Dividend yield (TTM)—

Revenue (annual)6.5M

Net income (annual)-63.7M

Social

What share of all stock conversation is about AKTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Mar 31

Aktis Oncology's shares ($AKTS) are trading higher after HC Wainwright raised its price target from $30 to $33.
The company has received FDA clearance for AKY-2519 IND applications, enabling a Phase 1b trial to begin in mid-2026.
Insider buys of $120 million worth of shares at current prices indicate potential confidence in the stock's future value.

Generated by AI

Sentiment

Of the messages about AKTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +0.86	87.54% +0.53
Bearish	—	—	0% -0.86	12.46% -0.53

Bullish· Dec 17

Akoustis Technologies, Inc. (AKTS) has the potential to run 200% with the right volume.
The stock is expected to experience a significant price increase, potentially reaching $0.07 from its current price of $0.035.
A delisting on the current exchange is approaching, which may lead to a BK trade and 100% gains on the move.

Bearish· Dec 17

$AKTS is at risk of being delisted due to non-compliance with Nasdaq listing requirements.
The company's bankruptcy status and potential for a 100% loss of investment is a significant concern.
Historical comparisons with companies like Hertz and Xtia, which faced similar challenges, suggest a potentially severe price drop for $AKTS.

Generated by AI

Topics

Of the messages about AKTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	88.35%
Analysts	—	—	100%	9.23%
Technical Analysis	—	—	0%	2.2%
Controversies	—	—	0%	0.22%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Jan 31

Akoustis Technologies (AKTS) reported record revenue for Q2 2022 with 96% sequential growth.
The company missed earnings expectations by $0.06, but beat revenue estimates.
AKTS reported a loss of $0.29 per share, which was higher than the consensus estimate of a loss of $0.19 per share.

Announcements· Jan 9

Aktis Oncology ($AKTS) priced a $318M IPO, making it the biotech sector's first offering of 2026 and the third-largest since 2024.
Eli Lilly invested $100M in the offering, anchoring the upsized IPO and signaling strong interest in the company's targeted radiopharmaceuticals.
Aktis Oncology's shares surged 50% on their Nasdaq debut, opening at $27 and reaching $29.16 before closing at $22.40, with strong institutional backing and Eli Lilly's support.

Technical Analysis· Nov 21

$AKTS needs to break $0.1456 to continue its upward trend.
The stock is forming a bull flag, with a potential breakout above $0.12.
The RSI is above 80, indicating a strong bull signal and a potential green flag for $AKTS.

Generated by AI

Community

Of the messages about AKTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	30.77%	6.89%
Newcomers	100%	100%	69.23%	93.11%

Regulars· Dec 17

The regulars are expecting a significant price increase in AKTS, potentially reaching $0.07 from $0.035, and are anticipating 100% gains on the move.
The regulars are watching for a potential bounce in AKTS, hoping for at least a 50% gain, and are considering a trade if the price reaches $0.05-$0.06.
The regulars are warning that AKTS is very bearish and may delist, potentially with a 4-hour notice, and are cautioning against taking on too much risk in a trade.

Newcomers· Jan 9

The IPO of Aktis Oncology, $AKTS, priced at $18.00 and raised $318M, with the company's market cap and EV valued at $890M and $370M, respectively.
Aktis Oncology's stock soared 62% in its Nasdaq debut, valuing the firm at $1.42B, with the company focusing on treatments for solid tumors.
The $AKTS IPO has been described as a biotech sector highlight, with Aktis Oncology's Nectin-4 targeted radiopharmaceutical drawing attention, and the company's pipeline and safety data being closely watched.

Generated by AI

Also Discussed

Investors talking about AKTS also mention

#	Name	Attention
1	Greenwave Technology Solutions, Inc.GWAV	0%0
2	Barnes & Noble Education Inc.BNED	0%0
3	Mustang Bio Inc.MBIO	0%0
4	PRST - Presto Automation, Inc.	——
5	Crown Electrokinetics Corp.CRKN	0%0
6	ZCAR - Zoomcar Holdings, Inc.	——
7	TPHS - Trinity Place Holdings Inc.	——
8	BRSH - Bruush Oral Care Inc.	——
9	Expion360 Inc.XPON	0%0
10	Nauticus Robotics Inc.KITT	0%0

Akoustis Technologies Inc.

Healthcare
Biotechnology

Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets. It leverages proprietary bulk acoustic wave (BAW) technology, including its microelectromechanical system (MEMS)-based XBAW manufacturing process, to produce high-performance filters optimized for high power, high frequency, and wide bandwidth applications. The company operates through two primary segments: Fabrication Services, which offers engineering review and backend packaging services, and RF Filters, focused on amplifier and filter product sales. Its solutions serve critical applications in smartphones, tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense systems. Akoustis Technologies Inc. also provides complementary products such as surface acoustic wave resonators, crystal resonators and oscillators, ceramic products, and back-end semiconductor supply chain services. Headquartered in Huntersville, North Carolina, the company plays a specialized role in advancing RF front-end modules for next-generation wireless connectivity.

Website

Location

17 Drydock Avenue

Boston, MA, 02210

United States

Social

What share of all stock conversation is about AKTS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Mar 31

Aktis Oncology's shares ($AKTS) are trading higher after HC Wainwright raised its price target from $30 to $33.
The company has received FDA clearance for AKY-2519 IND applications, enabling a Phase 1b trial to begin in mid-2026.
Insider buys of $120 million worth of shares at current prices indicate potential confidence in the stock's future value.

Generated by AI

Sentiment

Of the messages about AKTS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +0.86	87.54% +0.53
Bearish	—	—	0% -0.86	12.46% -0.53

Bullish· Dec 17

Akoustis Technologies, Inc. (AKTS) has the potential to run 200% with the right volume.
The stock is expected to experience a significant price increase, potentially reaching $0.07 from its current price of $0.035.
A delisting on the current exchange is approaching, which may lead to a BK trade and 100% gains on the move.

Bearish· Dec 17

$AKTS is at risk of being delisted due to non-compliance with Nasdaq listing requirements.
The company's bankruptcy status and potential for a 100% loss of investment is a significant concern.
Historical comparisons with companies like Hertz and Xtia, which faced similar challenges, suggest a potentially severe price drop for $AKTS.

Generated by AI

Topics

Of the messages about AKTS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	88.35%
Analysts	—	—	100%	9.23%
Technical Analysis	—	—	0%	2.2%
Controversies	—	—	0%	0.22%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Jan 31

Akoustis Technologies (AKTS) reported record revenue for Q2 2022 with 96% sequential growth.
The company missed earnings expectations by $0.06, but beat revenue estimates.
AKTS reported a loss of $0.29 per share, which was higher than the consensus estimate of a loss of $0.19 per share.

Announcements· Jan 9

Aktis Oncology ($AKTS) priced a $318M IPO, making it the biotech sector's first offering of 2026 and the third-largest since 2024.
Eli Lilly invested $100M in the offering, anchoring the upsized IPO and signaling strong interest in the company's targeted radiopharmaceuticals.
Aktis Oncology's shares surged 50% on their Nasdaq debut, opening at $27 and reaching $29.16 before closing at $22.40, with strong institutional backing and Eli Lilly's support.

Technical Analysis· Nov 21

$AKTS needs to break $0.1456 to continue its upward trend.
The stock is forming a bull flag, with a potential breakout above $0.12.
The RSI is above 80, indicating a strong bull signal and a potential green flag for $AKTS.

Generated by AI

Community

Of the messages about AKTS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	30.77%	6.89%
Newcomers	100%	100%	69.23%	93.11%

Regulars· Dec 17

The regulars are expecting a significant price increase in AKTS, potentially reaching $0.07 from $0.035, and are anticipating 100% gains on the move.
The regulars are watching for a potential bounce in AKTS, hoping for at least a 50% gain, and are considering a trade if the price reaches $0.05-$0.06.
The regulars are warning that AKTS is very bearish and may delist, potentially with a 4-hour notice, and are cautioning against taking on too much risk in a trade.

Newcomers· Jan 9

The IPO of Aktis Oncology, $AKTS, priced at $18.00 and raised $318M, with the company's market cap and EV valued at $890M and $370M, respectively.
Aktis Oncology's stock soared 62% in its Nasdaq debut, valuing the firm at $1.42B, with the company focusing on treatments for solid tumors.
The $AKTS IPO has been described as a biotech sector highlight, with Aktis Oncology's Nectin-4 targeted radiopharmaceutical drawing attention, and the company's pipeline and safety data being closely watched.

Generated by AI

Akoustis Technologies

Social

Mar 31

Sentiment

Bullish· Dec 17

Bearish· Dec 17

Topics

Earnings· Jan 31

Announcements· Jan 9

Technical Analysis· Nov 21

Community

Regulars· Dec 17

Newcomers· Jan 9

Also Discussed

Akoustis Technologies Inc.

Company Information

Location

Also Discussed

Social

Mar 31

Sentiment

Bullish· Dec 17

Bearish· Dec 17

Topics

Earnings· Jan 31

Announcements· Jan 9

Technical Analysis· Nov 21

Community

Regulars· Dec 17

Newcomers· Jan 9